Clinical Trials
50 trialsTesting Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Dana-Farber Cancer Institute
AMBITION
Japanese Foundation for Cancer Research
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Morpheus-panBC
Hoffmann-La Roche
Astefania
Hoffmann-La Roche
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
AZALEA
European Institute of Oncology
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Triple-B
The Netherlands Cancer Institute
MORPHEUS HR+BC
Hoffmann-La Roche
CAPTIV-8
British Columbia Cancer Agency
PROMETEO
SOLTI Breast Cancer Research Group
ATREZZO
SOLTI Breast Cancer Research Group
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
KATE3
Hoffmann-La Roche
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Syndax Pharmaceuticals
IMpassion050
Hoffmann-La Roche
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
ALICE
Oslo University Hospital
TONIC-3
The Netherlands Cancer Institute
ECLIPSE
Queen Mary University of London
ATRACTIB
MedSIR
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Consorzio Oncotech
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
TARA
Hoosier Cancer Research Network
ROME
Fondazione per la Medicina Personalizzata
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
MARIO-3
Infinity Pharmaceuticals, Inc.
AZTEC
Peter MacCallum Cancer Centre, Australia
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Hoffmann-La Roche
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Anastase
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
AWARE-1
Oncolytics Biotech
GELATO
The Netherlands Cancer Institute
AteBrO
Universitaire Ziekenhuizen KU Leuven
PROLOG
The Netherlands Cancer Institute
PREDIXIIHER2
Karolinska University Hospital
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
CONTESSA TRIO
Odonate Therapeutics, Inc.
KATE2
Hoffmann-La Roche
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Hoffmann-La Roche